Two Lawsuits Put Medicare's $440 Million Foreign-Price Pilot Before a Court — and the Precedent Is Worth Far More Than the Savings

GLOBE — the Global Benchmark for Efficient Drug Pricing model — is the administration's first Medicare payment program whose price input is set outside the United States. CMS finalized it on Sept. 30, published the rule Oct. 2, and set the legal effective date at Nov. 30, 2026. The program itself launches Jan. 1, 2027, with beneficiary coinsurance changes running Apr. 1, 2027 through Mar. 31, 2032 and rebate reconciliation continuing into 2034. Industry has answered with two complaints in two districts: PhRMA's Oct. 7 filing in the District of Columbia and the biotech groups' Nov. 6 filing in the Northern District of California.

The clock matters more than the complaints. GLOBE codifies on Nov. 30; the ZIP-code areas covering roughly a quarter of Original Medicare Part B beneficiaries must be picked by Dec. 31, 2026; voluntary international net-price reporting opens Jan. 1, 2027; and the first covered HCPCS list follows. Treat the next 90 days as a sequence of dated binary events rather than a single ruling — and note what is still missing: CMS has not named the manufacturers it expects to remain in scope, and has not published the drug list, so the molecule-level exposure is still unmeasurable.

The administration's justification has not changed with the numbers. CMS Administrator Dr. Mehmet Oz wrote that Medicare Part B patients and taxpayers have paid significantly more for prescription medications than people in comparable countries, and the agency puts the gap at more than four times what other developed countries pay for brand-name drugs. That framing is what makes GLOBE a template rather than a rounding error: a mechanism that imports foreign prices into American Medicare can be scaled to a far larger budget — as the Part D twin, GUARD, with an anticipated Jan. 1, 2027 start, intends to do.

The two complaints are complementary rather than duplicative. The District of Columbia case is a pure administrative-law record: authority, waiver scope, major questions, and the judicial review bar. The Northern District of California case adds spending and structural-constitutional theories no other GLOBE complaint has raised, and the plaintiffs say they collectively represent more than one-third of America's biotech companies. That breadth of constituency matters politically if a ruling survives appeal — but it also means the two forums will move at different speeds, and a narrow administrative ruling in one will not bind the other.

The precedent is what an investor is actually buying or selling. If Section 1115A can carry a foreign price benchmark for a five-year test, it can carry one for a commercial plan, a state Medicaid program or a mandatory rebate with a different trigger — and the administration's 17 announced most-favored-nation agreements with manufacturers sit directly on top of that authority. If the courts hold that a demonstration authority cannot replace a statutory rebate formula, the imported-pricing route closes for this administration and reference pricing survives only as trade negotiation, where it is voluntary, bilateral and reversible. A ruling either way re-prices the ceiling on American launch prices for a decade.

GLOBE replaces the domestic inflation test for selected Part B drugs with a foreign one. For each covered drug the per-unit benchmark is the greater of two numbers: the lowest country-level price among the 19 reference countries after economic adjustment for GDP and purchasing power, or the volume-weighted average of the manufacturer's own net prices across those countries, which manufacturers may submit voluntarily and which CMS will only use if every manufacturer of that drug submits. The rebate owed is the gap between the Part B inflation-rebate specified amount and that benchmark, applied to billing units for eligible beneficiaries, and it can never be smaller than the rebate already owed under the IRA's Part B inflation program. GLOBE is additive, not a substitute.

Two consequences follow that no one is modeling. First, launch economics: the benchmark relies on countries where a product is already sold, and a July 2026 study of 79 therapies in JAMA Health Forum found only 1.3% entered a qualifying foreign market within a year of US approval and 24.1% within five years. For most new launches the US would be benchmarked against legacy foreign prices set without competition, which is a ceiling on American pricing built from the quietest data point in the file. Second, trade policy is already moving the input. The April 2, 2026 proclamation imposed a 100% baseline Section 232 tariff on covered patented pharmaceuticals and ingredients, with treatment tied to MFN agreements and domestic manufacturing commitments; the UK arrangement of the same day pairs a 25% NHS net-price increase with US tariff protection to Jan. 19, 2029; and USTR opened a Section 301 case into Germany's underpayment in June. The US government is now bargaining for higher foreign prices and importing lower foreign prices at the same time.

The final rule excludes biosimilars from GLOBE and — the detail that matters — excludes the reference biologic too, once a biosimilar is on the US market. The model therefore taxes a branded Part B biologic exactly during its monopoly window and switches off as competition arrives. It is not a launch-pricing tax; it is a peak-price tax that expires on entry. For a company whose biggest Part B franchise is still pre-biosimilar, the design creates a dated incentive: either accept a lower US price under the benchmark, accelerate the biosimilar response, or rely on exclusion from the model and hope the covered list never reaches the molecule.

The policy mix makes the carve-out look deliberate. The 2025 reconciliation law widened the IRA's orphan exclusion, delaying Keytruda and Opdivo out of Medicare negotiation for now — a change the Congressional Budget Office priced at $8.8 billion of forgone federal savings over the coming decade. GLOBE's class screen covers oncology, rheumatology, immunology, ophthalmology and endocrinology for single-source drugs and sole-source biologics with more than $100 million of annual Original Medicare Part B spending, and it excludes orphan-only drugs but not drugs that merely carry an orphan indication alongside broader ones. Domestic negotiation was narrowed; imported reference pricing was not, and the biotech plaintiffs are asking a court to notice that asymmetry.

The pass-through arithmetic is straightforward. For the manufacturers, the entire seven-year rebate pool equals less than one-seventh of one percent of the $350 billion Medicare spends on Part B and Part D drugs in a single year, and it is spread across about four companies. For the wholesalers, Part B price compression is a revenue event rather than a margin event: McKesson and Cencora run gross margins of 3.6% and 4.1% on revenue bases of $403.4 billion and $337.4 billion, so a lower average selling price strips the top line while leaving the fee structure intact. For the plans, the cushion is thinner than the headline suggests — Humana earned $1.2 billion of net income on $129.7 billion of FY2025 revenue, a 0.9% margin, so GLOBE's net $440 million is trivial next to one bad year of margin slippage.

That is the point of the model: it is too small to break anything and precisely shaped to be reusable. GLOBE pays beneficiaries almost nothing, taxes manufacturers almost nothing, and moves a country's reimbursement file into the definition of an American rebate. A narrow, cheap rule is the easiest kind of precedent for an administration to build on — and the Part D version of the same design, GUARD, is aimed at a drug budget an order of magnitude larger.

Two lawsuits now ask whether Health and Human Services can build a foreign price ceiling into Medicare without Congress, and the answer will price every launch decision that follows. The money is a rounding error — $440 million against $350 billion of annual Medicare drug spending — and CMS narrowed the model until roughly four manufacturers remained, 0.3% of Part B beneficiaries benefited, and biosimilars sat outside the net. What survives is a mechanism that makes a foreign reimbursement file an input to a US rebate, a rebate that stacks on top of the Inflation Reduction Act's, and a trade apparatus already bargaining for higher foreign prices in exchange for tariff relief. For Merck, Bristol-Myers Squibb, Johnson & Johnson and Amgen the near-term earnings risk is negligible and the optionality risk is not: a ruling validating imported reference pricing makes the world's pricing committees a permanent input into American launch pricing. Size the exposure on precedent, not on the rebate line.